PEARLAND, TEXAS, UNITED STATES, October 7, 2021
Altus Biologics, a leader in infusion management services, announced today that they are expanding their neurology drug offering to include Aduhelm (also known as Aducanumab).
About Aduhelm
Aduhelm is the first disease-modifying, FDA-approved therapy for the treatment of Alzheimer’s disease in almost two decades. Aducanumab is an amyloid beta-directed antibody designed to treat mild dementia or mild cognitive impairment patients.
Developed by Biogen, Aduhelm targets amyloid-beta plaques which build up in the brain, causing neurons to die. Aduhelm attaches itself to these plaques triggering the body’s defenses to respond and destroy the amyloid-beta plaques.
Aduhelm Adminstration
Aduhelm is an intravenous infusion administered every four weeks. Infusions typically last approximately an hour. Physician practices managed by Altus Biologics can now provide this life-changing drug to patients in their offices.
A Light of Hope for Alzheimer’s Patients
The news of the expanded drug list announced by Altus Biologics brings a light of hope to Alzheimer’s patients nationwide.
Scientists involved in clinical trials believe Aduhelm can prevent neuron degeneration due to amyloid-beta plaque buildup and slow down or even prevent memory and cognitive deterioration in the early stages of Alzheimer’s disease.
Today, the biggest hurdle for patients is access to the medication. That is why today’s announcement has generated much anticipation and excitement among the medical community, patients, and their caregivers. Altus adding Aduhelm to its list of neurology drugs means access to this newly FDA-approved drug is now easier than ever.
Patient advocacy is at the core of Altus Biologics. As stated by Mark Elliot, President of Altus Biologics, “We work with neurology practices across the country to ensure patients have access to more affordable cutting-edge biologic therapies in a comfortable and convenient location surrounded by a trusted team of medical professionals offering them more personalized care.”
Through Altus Biologics’ in-office management solutions, physicians can expand their level of care by offering infusion therapy in their current location.
The in-office infusion model has proven to increase patient satisfaction and treatment compliance by offering patients a broader and more convenient network to receive their infusion therapies.
Receiving treatment in a convenient and familiar setting is imperative for patients with neurodegenerative conditions like Alzheimer’s, as it reduces anxiety levels from being exposed to unfamiliar or crowded environments.
About Altus Biologics
Headquartered in Pearland, Texas, Altus Biologics is a leading in-office biologics management solution provider.
Altus Biologics offers specialty in-office infusion services to adult and pediatric patients with chronic diseases. Their solutions include neurology, respiratory, GI, and rheumatology.
The company manages your private in-office infusion center, including administrative services, drug acquisition, patient services, and clinical services.
